Oncotarget

Research Papers:

Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes

Wen-Ling Liao, Wen-Jane Lee, Ching-Chu Chen, Chieh Hsiang Lu, Chien-Hsiun Chen, Yi-Chun Chou, I-Te Lee, Wayne H-H Sheu, Jer-Yuarn Wu, Chi-Fan Yang, Chung-Hsing Wang and Fuu-Jen Tsai _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:18050-18058. https://doi.org/10.18632/oncotarget.14951

Metrics: PDF 1009 views  |   HTML 1541 views  |   ?  


Abstract

Wen-Ling Liao1,2,*, Wen-Jane Lee3,*, Ching-Chu Chen4,5,*, Chieh Hsiang Lu6,7,8,*, Chien-Hsiun Chen5,9, Yi-Chun Chou9, I-Te Lee10,11,12, Wayne H-H Sheu10,12,13,14, Jer-Yuarn Wu5,9, Chi-Fan Yang9, Chung-Hsing Wang15,16, Fuu-Jen Tsai5,17,18

1Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan

2Center for Personalized Medicine, China Medical University Hospital, Taichung, Taiwan

3Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan

4Division of Endocrinology and Metabolism, Department of Medicine, China Medical University Hospital, Taichung, Taiwan

5School of Chinese Medicine, China Medical University, Taichung, Taiwan

6Department of Internal Medicine, Ditmanson Medical Foundation, Chiayi Christian Hospital, Chiayi City, Taiwan

7Department of Nursing, College of Nursing and Health Sciences, DAYEH University, Changhua, Taiwan

8Department of Business management, College of Management, National Chung Cheng University, Chia-yi, Taiwan

9National Center for Genome Medicine, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan

10Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans Hospital, Taichung, Taiwan

11School of Medicine, Chung Shan Medical University, Taichung, Taiwan

12School of Medicine, National Yang-Ming University, Taipei, Taiwan

13School of Medicine, National Defense Medical Center, Taipei, Taiwan

14Institute of Medical Technology, National Chung-Hsing University, Taichung, Taiwan

15Department of Genetics and Metabolism, Children’s Hospital of China Medical University, Taichung, Taiwan

16School of Medicine, China Medical University, Taichung, Taiwan

17Department of Medical Genetics, China Medical University Hospital, Taichung, Taiwan

18Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan

*These authors have contributed equally to this work

Correspondence to:

Fuu-Jen Tsai, email: d0704@www.cmuh.org.tw

Keywords: DPP-4 inhibitors, pharmacogenetics, Taiwanese, type 2 diabetes

Received: January 29, 2016    Accepted: January 03, 2017    Published: February 01, 2017

ABSTRACT

Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral anti-hyperglycemic drugs enabling effective glycemic control in type 2 diabetes (T2D). Despite DPP-4 inhibitors’ advantages, the patients’ therapeutic response varies. In this retrospective cohort study, 171 Taiwanese patients with T2D were classified as sensitive or resistant to treatment based on the mean change in HbA1c levels. Using an assumption-free genome-wide association study, 45 single nucleotide polymorphisms (SNPs) involved in the therapeutic response to DPP-4 inhibitors (P < 1 × 10-4) were identified at or near PRKD1, CNTN3, ASK, and LOC10537792. A SNP located within the fourth intron of PRKD1 (rs57803087) was strongly associated with DPP-4 inhibitor response (P = 3.2 × 10-6). This is the first pharmacogenomics study on DPP-4 inhibitor treatment for diabetes in a Taiwanese population. Our data suggest that genes associated with β-cell function and apoptosis are involved in the therapeutic effect of DPP-4 inhibitors, even in the presence of additional oral anti-diabetic drugs. Our findings provide information on how genetic variants influence drug response and may benefit the development of personalized medicine.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14951